Arvinas and Pfizer Share Early Phase 1b Results from TACTIVE-U Sub-Study on Vepdegestrant Plus Abemaciclib at the 2024 San Antonio Breast Cancer Symposium.

Halia Therapeutics reports encouraging preliminary results and moves to the next phase of its Phase 2 trial for HT-6184 in patients with low-risk myelodysplastic syndromes (LR-MDS).

Moberg Pharma announces key results from its phase 3 trial in North America and will reclaim the EU rights to MOB-015.

Astria Therapeutics has received FDA approval for its IND application concerning STAR-0310, a monoclonal antibody targeting OX40, aimed at treating atopic dermatitis.

Apogee Therapeutics has dosed the initial participants in a Phase 1 clinical trial for APG333.

NextCure, announced FDA approval of its IND application to begin a Phase 1 trial for LNCB74.

Protara reports favorable outcomes from the current Phase 2 ADVANCED-2 study of TARA-002 in NMIBC patients.

Affimed N.V. has revealed the oral presentation of AFM28 data at the 66th ASH Annual Meeting and Exposition.

Electra Therapeutics Shares Favorable Phase 1b Trial Outcomes for ELA026 in sHLH During an ASH 2024 Oral Presentation.

Immune-Onc Therapeutics Reveals Latest Phase 1b Trial Results for IO-202, Showcasing Positive Efficacy and Safety in CMML Patients, at the 2024 ASH Meeting.

Star Therapeutics Unveils Midpoint Clinical Results for VGA039 in VWD Patients at 2024 ASH Conference.

Auron Therapeutics has released data on its primary project, AUTX-703, at the 66th ASH Annual Meeting and Exposition in San Diego, CA.